Prevalence and risk factors for hepatitis C virus infection in continuous ambulatory peritoneal dialysis patients

Background. Studies on hepatitis C virus antibodies (Anti-HCV) in CAPD patients are scarce and include a small number of patients. Nevertheless, risk factors related to Anti-HCV in these patients are still subject to controversy. Purpose of the study. To analyse the incidence and risk factors associ...

Full description

Saved in:
Bibliographic Details
Published inNephrology, dialysis, transplantation Vol. 11; no. 6; pp. 1109 - 1112
Main Authors Górriz, J. L., Miguel, A., García-Ramón, R., Pérez-Contreras, J., Olivares, J., Gómez-Roldán, C., AlvariñO, J., Lanuza, M.
Format Journal Article
LanguageEnglish
Published Oxford University Press 01.06.1996
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background. Studies on hepatitis C virus antibodies (Anti-HCV) in CAPD patients are scarce and include a small number of patients. Nevertheless, risk factors related to Anti-HCV in these patients are still subject to controversy. Purpose of the study. To analyse the incidence and risk factors associated with the presence of Anti-HCV in CAPD patients. Methods. We studied 255 patients from five different treatment centres of our region. The analysis was repeated after excluding 161 patients who had previously received haemodialysis treatment at least once. Anti-HCV testing was made by the 2nd-generation ELISA. As a supplementary test we used RIBA-4 in three centers and INNOLIA in the other two. Risk factors were analysed using logistic regression model for multivariate analysis. Results. In the whole group, 29 patients (11.4%) were anti-HCV positive. Logistic regression analysis determined the following variables as independent risk factors: hepatitis previous to CAPD (P<0.0001, odds ratio (OR): 44.9), Anti HBc positivity (P=;0.019, OR: 9.24), blood transfusions previous to CAPD (P=;0.015, OR: 1.05) and CAPD duration (P=0.025, OR: 1.02). When patients who had previously undergone haemodialysis were excluded, the prevalence of HCV antibodies was 8.5% (8/94). In this group multivariate analysis showed that Anti-HCV positivity correlated with hepatitis previous to CAPD (P<0.0003, OR: 126) and Anti HBc positivity (P=0.002, OR: 41.9). Conclusions. Our prevalence of hepatitis C virus (HCV) infection in CAPD patients was lower than other renal replacement therapy modalities, and correlated to events occurring mainly before starting CAPD treatment. This technique could be considered as low risk for HCV infection.
Bibliography:istex:54AD60505E47465C2F53D47AAD580260CFB07FE6
ArticleID:11.6.1109
ark:/67375/HXZ-G8VPJJRR-Z
Correspondence and offprint requests to: Jose Luis Górriz MD, Servicio de Nefrología, Hospital Dr. Peset, Avda. Gaspar Aguilar, 90, 46017 Valencia, Spain
ISSN:0931-0509
1460-2385
DOI:10.1093/oxfordjournals.ndt.a027464